Swiss Look to Expand Pediatric Trials
The Swiss Research Network of Clinical Pediatric Hubs (SwissPedNet) is seeking to promote clinical research in pediatrics in Switzerland.
Along with the Swiss Association of Paediatrics, SSP/SGP, SwissPedNet has issued a request for study proposals in pediatric health services research, and has set aside 120,000 Swiss Francs (around $121,000) to fund the initiative. Clinical research includes all investigations relating to patients seen either in private practices or clinics or both.
Switzerland’s five university children’s hospitals (Basel, Bern, Geneva, Lausanne and Zurich), as well as the three children’s hospitals of Aarau, Lucerne, and St. Gallen, set up SwissPedNet in 2012. Its task is to promote, facilitate, coordinate, and conduct clinical trials devoted to children, ranging from newborns to adolescents, in all pediatric disciplines. The ultimate goal is to enhance clinical research in paediatrics, both by supporting pediatric clinician scientists to foster their commitment to high-quality clinical research and by encouraging increased acceptance in the community of trials in children.
On November 20, 2015 the EOC Ticino’s department of pediatrics became the ninth clinical pediatric hub of SwissPedNet. In addition, the Swiss pediatric registry center at ISPM in Bern and SwissPedPha, the platform for pediatric pharmacology, are ordinary members of SwissPedNet.
SwissPedNet receives federal funding in the framework of the roadmap 2017-2020 (www.swisspednet.ch), and is closely linked to the Swiss Clinical Trial Organisation SCTO and its network of CTUs (www.scto.ch).
The submission deadline for new proposals is February 28, 2018. Click here for more details.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
FOCUS Trial Results Show Solriamfetol Significantly Reduces ADHD Symptoms, Severity in Adults
March 27th 2025Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention-deficit hyperactivity disorder symptoms and disease severity in adults compared to placebo, with a favorable safety and tolerability profile.
